Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials
SARS-CoV-2 mRNA疫苗(SYS6006)在18岁及以上中国受试者中进行初次免疫的安全性和免疫原性:两项随机、观察者盲法、安慰剂对照和剂量递增的1期临床试验
期刊:Human Vaccines & Immunotherapeutics
影响因子:3.5
doi:10.1080/21645515.2023.2285089
Chen, Gui-Ling; Qiu, Yuan-Zheng; Wu, Kai-Qi; Wu, Ying; Wang, Yuan-Hui; Zou, Yu-Ying; Peng, Cong-Gao; Zhao, Jie; Su, Chang; Ma, Jun-Heng; Ni, Shao-Nan; Wang, Xing; Jin, Ting-Han; Jiang, Qi; Guo, Tong; Xu, Yan; Huang, Chao-Chao; Zhang, Qing; Liu, Kai-Li; Ji, Li; Yang, Han-Yu; Li, Chun-Lei; Su, Yu-Wen; Lu, Xiang; Li, Lan-Juan